These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7987083)

  • 1. [Determination of kidney function in patients with ovarian cancer treated with chemotherapy: calculation versus measurement of creatine clearance].
    Küng F; Köchli OR; Seifert B; Haller U
    Gynakol Geburtshilfliche Rundsch; 1994; 34(3):157-61. PubMed ID: 7987083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
    Calvert AH; Boddy A; Bailey NP; Siddiqui N; Humphreys A; Hughes A; Robson L; Gumbrell L; Thomas H; Chapman F
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):91-8; discussion 99-100. PubMed ID: 7481870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate.
    Robinson BA; Frampton CM; Colls BM; Atkinson CH; Fitzharris BM
    Aust N Z J Med; 1990 Oct; 20(5):657-62. PubMed ID: 2285382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
    Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
    Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of relative factors of bone marrow suppression after chemotherapy with carboplatin and paclitaxel on the patients with ovarian cancer].
    Ding D; Kong WM
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):188-92. PubMed ID: 21575452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
    Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
    Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
    Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
    Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
    Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb-IV ovarian carcinoma: cisplatin-paclitaxel vs. carboplatin-paclitaxel. AGO Protocol Ovar-3].
    Mettler L
    Zentralbl Gynakol; 1996; 118(6):379-4. PubMed ID: 8768017
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy.
    Cavalcanti E; Barchiesi V; Cerasuolo D; Di Paola F; Cantile M; Cecere SC; Pignata S; Morabito A; Costanzo R; Di Maio M; Perrone F
    Anal Cell Pathol (Amst); 2016; 2016():4918325. PubMed ID: 28078200
    [No Abstract]   [Full Text] [Related]  

  • 15. The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer.
    Kim SW; Paek J; Nam EJ; Kim SH; Kim JH; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2010 Oct; 152(2):195-9. PubMed ID: 20576343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
    Neijt JP; Engelholm SA; Witteveen PO; Tuxen MK; Sørensen PG; Hansen M; Hirsch F; Sessa C; de Swart C; van Houwelingen HC; Lund B; Hansen SW
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-36-S15-39. PubMed ID: 9346220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The value of platinum dose intensity in first-line therapy on subsequent disease follow-up of epithelial ovarian carcinoma].
    Gruböck K
    Wien Klin Wochenschr; 1994; 106(11):362-6. PubMed ID: 8053205
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
    Neijt JP; Engelholm SA; Tuxen MK; Sorensen PG; Hansen M; Sessa C; de Swart CA; Hirsch FR; Lund B; van Houwelingen HC
    J Clin Oncol; 2000 Sep; 18(17):3084-92. PubMed ID: 10963636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.